ZTS
Zoetis Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 944.24K | $65.94M | n/a | −1 |
| Q2 2026 | 173 | +5 | 278.21M | $20.02B | +9 | −5 |
| Q1 2026 | 172 | -5 | 287.89M | $34.03B | +1 | −7 |
| Q4 2025 | 176 | -2 | 318.69M | $40.10B | +3 | −4 |
| Q3 2025 | 25 | -1 | 154.48M | $22.59B | n/a | −2 |
| Q2 2025 | 24 | +2 | 132.57M | $20.67B | +2 | n/a |
| Q1 2025 | 19 | 0 | 50.59M | $8.32B | n/a | n/a |
| Q4 2024 | 19 | +1 | 54.43M | $8.86B | +1 | n/a |
| Q3 2024 | 17 | 0 | 31.69M | $6.18B | +1 | −1 |
| Q2 2024 | 17 | n/a | 38.28M | $6.63B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 439.48K | -43.6% | $30.69M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 2 | Ninety One UK Ltd | 302.93K | -2.1% | $21.15M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 3 | Wealth Enhancement Advisory… | 177.55K | +112.1% | $12.42M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | TD Waterhouse Canada Inc. | 24.28K | +397.0% | $1.68M | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Robeco Institutional Asset… | $1.83M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1,596 holders, 404.54M shares, $46.32B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.